Ascendis to Unveil Phase 3 PaTHway and 52-Week COACH Trial Data at ENDO 2026
ASND•Ascendis Pharma will present Phase 3 PaTHway results for TransCon PTH in hypoparathyroidism and 52-week Phase 2 COACH data for Navepegritide with Lonapegsomatropin in achondroplasia at ENDO 2026 in Chicago. Three posters will cover 156-week productivity gains, prevalence of hypoparathyroidism and two-year SkybriGHt registry safety/effectiveness of Lonapegsomatropin in pediatric GHD.
1. Conference Presentation Schedule
Ascendis Pharma will deliver two oral presentations at ENDO 2026 in Chicago on June 13 and June 15 focused on hypoparathyroidism and achondroplasia, alongside three poster sessions on June 14 showcasing long-term rare endocrine disease data.
2. Hypoparathyroidism and Achondroplasia Data
The oral on June 13 will present Phase 3 PaTHway results for TransCon PTH demonstrating long-term safety and efficacy in adult hypoparathyroidism, while the June 15 session will reveal 52-week Phase 2 COACH findings for Navepegritide plus Lonapegsomatropin in children with achondroplasia.
3. Pediatric GHD and SkybriGHt Registry
Poster SUN-201 will highlight two-year safety and effectiveness data for Lonapegsomatropin in 100 pediatric growth hormone deficiency patients from the SkybriGHt registry, complementing two hypoparathyroidism prevalence and work productivity posters also on display.
